Lung Cancers With Rare EGFR Mutations Being Tackled by Novel Agents
Last Updated: Wednesday, June 16, 2021
Next-generation inhibitors of epidermal growth factor receptor (EGFR) exon 20 insertion mutations showed promise in patients with advanced non–small cell lung cancer (NSCLC) in early-phase trials presented during the International Association Society for Lung Cancer 2020 World Conference on Lung Cancer in Singapore, which was held virtually in January 2021.
Advertisement
News & Literature Highlights